Blood cancer is one of the most prevalent forms of cancer worldwide, associated with a significant mortality rate. Genes 2Me provides comprehensive next-generation sequencing (NGS) solutions for the identification of genetic variants associated with hematological malignancies. This data offers a holistic perspective for understanding and monitoring disease severity. The G2M Blood Cancer Panel encompasses three major types of blood cancers: Myeloid Leukemia, Lymphoid Leukemia, and Lymphoma.

Alterations in functioning of bone marrow due to mutations leads to Myeloid Leukemia.This is a condition where bone marrow produces abnormal amounts of blood cells. Genes 2Me offers a high accuracy NGS panel for identification of significant mutations that lead to Myeloid Leukemia. The panel covers a wide range of genes associated with Myeloid leukemia leading to a generating comprehensive insight into the patient’s genomic profile.

Lymphoid Leukemia is neoplastic proliferation of mature lymphoid cells affecting blood, bone marrow and other lymphoid organs. It is majorly classified based on the morphology and mature lymphoid cells involved in neoplasm. Acute Lymphoblastic Leukemia affects new or immature cells making them remain immature and lack normal functions. Genes 2Me has designed a hybridization based NGS panel to target clinically significant mutations associated with Lymphoid Leukemia. This panel allows clinicians to have a detailed approach for developing personalized treatment.

Lymphoma is attributed to the cancer of the cells from the lymph system. Sequencing the complete coding regions and hotspots, covering clinically relevant genes in order to identify clinically relevant genes has been a promising approach for monitoring and managing the disease severity. Gene 2Me has developed a panel to focus on the genes that lead to lymphatic cancer. The panel helps in identifying genetic variants within the clinically relevant genes to map significant somatic mutations in the coding region.